Short Duration Combination Therapy With Daclatasvir, Asunaprevir, BMS-791325 and Sofosbuvir in Subjects Infected With Chronic Hepatitis-C (FOURward Study)

Allocation:

Initial Therapy: Randomized Controlled Trial: Participants are assigned to intervention
groups by chance

Rescue Therapy: Nonrandomized Trial: Participants are expressly assigned to intervention
groups through a non-random method such as physician choice

Number of Arms:

Initial Therapy: 2 Groups

Rescue Therapy: 2 Groups

For more information regarding BMS clinical trial participation, please visit
www.BMSStudyConnect.com.

Inclusion Criteria:

- Males and Females ≥18 years of age, inclusive

- Chronic HCV infection Genotype 1 only

- Non-cirrhotic

- Treatment naive subjects with no previous exposure to an Interferon formulation (ie,
IFNα, pegIFNα), ribavirin (RBV) or HCV Direct Acting Antiviral (DAA) (protease,
polymerase inhibitor, etc.)

Exclusion Criteria:

- HCV Genotype other than Genotype 1

- Documented or suspected hepatocellular carcinoma

- Evidence of decompensated liver disease

- Contraindication(s) to Peg/RBV therapy